NasdaqGS - Delayed Quote • USD
Collegium Pharmaceutical, Inc. (COLL)
At close: April 24 at 4:00 PM EDT
After hours: April 24 at 4:02 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 4 | 4 |
| Avg. Estimate | 0.75 | 0.69 | 2.95 | 3.67 |
| Low Estimate | 0.7 | 0.62 | 2.6 | 3.45 |
| High Estimate | 0.78 | 0.73 | 3.25 | 3.85 |
| Year Ago EPS | -0.51 | 0.34 | 1.29 | 2.95 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 6 |
| Avg. Estimate | 147.49M | 142.23M | 583.51M | 595.91M |
| Low Estimate | 145.98M | 139.9M | 579.5M | 580.3M |
| High Estimate | 149.47M | 145.17M | 588.4M | 605.76M |
| Year Ago Sales | 142.39M | 138.4M | 566.77M | 583.51M |
| Sales Growth (year/est) | 3.60% | 2.80% | 3.00% | 2.10% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 0.31 | 0.29 | 0.52 | 0.66 |
| EPS Actual | -0.51 | 0.34 | 0.53 | 0.82 |
| Difference | -0.82 | 0.05 | 0.01 | 0.16 |
| Surprise % | -264.50% | 17.20% | 1.90% | 24.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.75 | 0.69 | 2.95 | 3.67 |
| 7 Days Ago | 0.75 | 0.69 | 2.95 | 3.67 |
| 30 Days Ago | 0.75 | 0.69 | 2.95 | 3.67 |
| 60 Days Ago | 0.62 | 0.69 | 2.74 | 8.11 |
| 90 Days Ago | 0.83 | 0.92 | 3.2 | 8.11 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | COLL | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 247.10% | -- | -- | 1.50% |
| Next Qtr. | 102.90% | -- | -- | 11.40% |
| Current Year | 128.70% | -- | -- | 5.20% |
| Next Year | 24.40% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 0.55% | -- | -- | 11.09% |
| Past 5 Years (per annum) | 26.50% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Needham: Buy to Buy | 4/11/2024 |
| Maintains | Truist Securities: Buy to Buy | 2/26/2024 |
| Reiterates | Piper Sandler: Overweight to Overweight | 2/23/2024 |
| Reiterates | Needham: Buy to Buy | 2/2/2024 |
| Maintains | Needham: Buy to Buy | 1/4/2024 |
| Maintains | Truist Securities: Buy to Buy | 1/4/2024 |
Related Tickers
ANIP ANI Pharmaceuticals, Inc.
65.43
-1.07%
SUPN Supernus Pharmaceuticals, Inc.
30.26
+1.04%
ALKS Alkermes plc
24.65
+1.61%
TARO Taro Pharmaceutical Industries Ltd.
42.20
-0.07%
IRWD Ironwood Pharmaceuticals, Inc.
8.10
-2.53%
AMPH Amphastar Pharmaceuticals, Inc.
41.00
+0.22%
PCRX Pacira BioSciences, Inc.
25.90
-3.39%
DCPH Deciphera Pharmaceuticals, Inc.
14.62
-0.34%
EGRX Eagle Pharmaceuticals, Inc.
4.5500
-4.61%
PETQ PetIQ, Inc.
16.53
-0.42%